Market Overview:
3D bioprinting is a type of 3D printing that deals with living cells and tissues and uses cell-based inks. 3D bioprinters can create biomimetic environments with precise architectural standards and biochemical cues to guide cell organization for tissue regeneration. The ability to print live and functional tissues from 3D models is ideal for regeneration medicines, drug discovery and toxicity testing.
Market key trends:
The 3D bioprinting market is driven primarily by the increasing prevalence of chronic diseases and trauma injuries. For instance, according to the World Health Organization, cardiovascular diseases account for over 17.9 million deaths globally every year. The implementation of 3D bioprinting technologies for developing artificial tissues and organs could help to treat such chronic medical conditions. Another key trend aiding the market growth includes continuous technological advancements. Various companies are focusing on developing bioprinters integrated with multiple bioinks, cell types and growth factors for increased printing resolution and complexity to biofabricate tissues similar to native tissues. Such developments are projected to augment the penetration of 3D bioprinting in the healthcare sector during the forecast period.
The global 3d Bioprinting Market Size is estimated to be valued at US$ 1281.57 Mn in 2023 and is expected to exhibit a CAGR of 21.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global 3D bioprinting market can be segmented based on technology, material, application, and end user. Based on technology, the Inkjet-based bioprinting segment is expected to dominate the market during the forecast period. Inkjet bioprinting allows higher resolution printing and is compatible with a wide range of biomaterials such as polyvinyl alcohol, gelatine, collagen, hyaluronic acid and fibrin, making it suitable for various tissue engineering applications.
Key Takeaways
The global 3D bioprinting market is expected to witness high growth, exhibiting a CAGR of 21% over the forecast period, due to increasing investments in healthcare infrastructure and R&D activities for tissue engineering applications.
Regional analysis
North America is expected to dominate the global 3D bioprinting market during the forecast period. This is attributed to presence of major players and availability of developed healthcare infrastructure and funding to support research activities in the region. Asia Pacific region is anticipated to exhibit the fastest growth over the forecast period owing to rising healthcare expenditure, improving access to healthcare facilities and growing medical tourism industry in the emerging economies of China and India.
Key players
Major companies involved in the global 3D printing market are 3D Systems Corporation, Cyfuse Biomedical KK, GeSIM GmbH, 3D Bioprinting Solutions, Aspect Biosystems Ltd., Organovo Holdings Inc., ARCAM AB (GE Company), Cellink AB, RegenHU SA, REGEMAT 3D, EnvisionTEC GmbH and Stratasys Ltd. Key players operating in the 3d bioprinting market are focusing on product innovations and launches to consolidate their market position.
